CoChat

Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes

Open access
Griffith, David A., Kung, Daniel W., Esler, William P., Amor, Paul A., Bagley, Scott W., Beysen, Carine, Carvajal-Gonzalez, Santos, Doran, Shawn D., Limberakis, Chris, Mathiowetz, Alan M., McPherson, Kirk, Price, David A., Ravussin, Eric, Sonnenberg, Gabriele E., Southers, James A., Sweet, Laurel J., Turner, Scott M., Vajdos, Felix F. · 2014 · Journal of Medicinal Chemistry
Cited by 90

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Acetyl-CoA carboxylase (ACC) inhibitors offer significant potential for the treatment of type 2 diabetes mellitus (T2DM), hepatic steatosis, and cancer. However, the identification of tool compounds suitable to test the hypothesis in human trials has been challenging. An advanced series of spirocyclic ketone-containing ACC inhibitors recently reported by Pfizer were metabolized in vivo by ketone reduction, which complicated human pharmacology projections. We disclose that this metabolic reduction can be greatly attenuated through introduction of steric hindrance adjacent to the ketone carbonyl. Incorporation of weakly basic functionality improved solubility and led to the identification of 9 as a clinical candidate for the treatment of T2DM. Phase I clinical studies demonstrated dose-proportional increases in exposure, single-dose inhibition of de novo lipogenesis (DNL), and changes in indirect calorimetry consistent with increased whole-body fatty acid oxidation. This demonstration of target engagement validates the use of compound 9 to evaluate the role of DNL in human disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/jm5016022

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 90

Metadata

Authors
Griffith, D. A., Kung, D. W., Esler, W. P., Amor, P. A., Bagley, S. W., Beysen, C., Carvajal-Gonzalez, S., Doran, S. D., Limberakis, C., Mathiowetz, A. M., McPherson, K., Price, D. A., Ravussin, E., Sonnenberg, G. E., Southers, J. A., Sweet, L. J., Turner, S. M., & Vajdos, F. F.
Venue
Journal of Medicinal Chemistry
Published
2014-12-11
Volume
57
Issue
24
Pages
10512-10526
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W1974937838
Cited by
90
References
4
FWCI
1.46
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes. https://app.cochat.ai/papers/10.1021/jm5016022
The paper
Griffith, D. A., Kung, D. W., Esler, W. P., Amor, P. A., Bagley, S. W., Beysen, C., Carvajal-Gonzalez, S., Doran, S. D., Limberakis, C., Mathiowetz, A. M., McPherson, K., Price, D. A., Ravussin, E., Sonnenberg, G. E., Southers, J. A., Sweet, L. J., Turner, S. M., & Vajdos, F. F. (2014). Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm5016022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.